Marker Therapeutics Q3 net loss narrows to $6.9M; FDA grant awarded for AML trial

Marker Therapeutics, Inc.

2022-Q3 EPS reported -$0.31 revenue$5,704,401

Net loss of $6.9M in Q3 2022, compared to $12.4M loss in Q3 2021.
Cash and equivalents $18.1M as of Sept 30, 2022; grant income $1.0M, related party service revenue $2.95M.
Awarded $2M FDA Orphan Products Grant to support Phase 2 ARTEMIS trial of MT-401 in post-transplant AML.
All six patients in Cohorts 4/5 treated with new manufacturing process; no DLTs; efficacy data expected by year-end.
FDA cleared IND for Phase 1 MT-601 in relapsed/refractory non-Hodgkin lymphoma; first patient expected Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Marker Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income $6.9 million.

Period: the quarter ended September 30, 2022
Net income: $6.9 million
Result: reported results

Exact text from the filing

Marker reported a net loss of $6.9 million for the quarter ended September 30, 2022, compared to a net loss of $12.4 million for the quarter ended September 30, 2021.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Marker Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-117148

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.